These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

513 related items for PubMed ID: 33494127

  • 41. Circulating Epstein-Barr virus DNA level post induction chemotherapy contributes to prognostication in advanced-stage nasopharyngeal carcinoma.
    Chen FP, Luo YS, Chen K, Li JY, Huo LQ, Shi L, Ou-Yang Y, Cao XP.
    Eur J Cancer; 2021 Jul; 151():63-71. PubMed ID: 33964573
    [Abstract] [Full Text] [Related]

  • 42. Comparing three induction chemotherapy regimens for patients with locoregionally advanced nasopharyngeal carcinoma based on TNM stage and plasma Epstein-Barr virus DNA level.
    Liu SL, Sun XS, Xie HJ, Chen QY, Lin HX, Liang H, Liang YJ, Li XY, Yan JJ, Lin C, Yang ZC, Guo SS, Liu LT, Tang QN, Du YY, Tang LQ, Guo L, Mai HQ.
    BMC Cancer; 2020 Feb 03; 20(1):89. PubMed ID: 32013967
    [Abstract] [Full Text] [Related]

  • 43.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 44.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 45. [Prognostic significance of serum anti-Epstein-Barr virus antibodies in nasopharyngeal carcinoma].
    Cai YL, Li J, Lu AY, Zhong WM, Zheng YM, Gao JQ, Zeng H, Chen WS, Liang W, Tang MZ.
    Zhonghua Shi Yan He Lin Chuang Bing Du Xue Za Zhi; 2013 Apr 03; 27(2):119-22. PubMed ID: 24044217
    [Abstract] [Full Text] [Related]

  • 46. [Detection of serum Epstein-Barr virus antibody level by ELISA in normal populations and nasopharyngeal carcinoma patients in Zhongshan City of China].
    Cheng MT, Cheng WM, Ji MF, Liang JS.
    Di Yi Jun Yi Da Xue Xue Bao; 2002 Sep 03; 22(9):817-8, 822. PubMed ID: 12297441
    [Abstract] [Full Text] [Related]

  • 47. Circulating Epstein-Barr virus microRNAs miR-BART7 and miR-BART13 as biomarkers for nasopharyngeal carcinoma diagnosis and treatment.
    Zhang G, Zong J, Lin S, Verhoeven RJ, Tong S, Chen Y, Ji M, Cheng W, Tsao SW, Lung M, Pan J, Chen H.
    Int J Cancer; 2015 Mar 01; 136(5):E301-12. PubMed ID: 25213622
    [Abstract] [Full Text] [Related]

  • 48.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 49.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 50. [Combined detection of Epstein-Barr virus antibodies for serodiagnosis of nasopharyngeal carcinoma].
    Cai YL, Zheng YM, Wang W, Wei Y, Shen XX, Cheng JR, Wu YS, Gao JQ, Zhong WM, Li J.
    Nan Fang Yi Ke Da Xue Xue Bao; 2010 Dec 01; 30(12):2746-8. PubMed ID: 21177196
    [Abstract] [Full Text] [Related]

  • 51. Early change of plasma Epstein-Barr virus DNA load and the viral lytic genome level could positively predict clinical outcome in recurrent or metastatic nasopharyngeal carcinoma receiving anti-programmed cell death 1 monotherapy.
    Lin S, Zhou H, Chen G, Xue J, Liu Q, Li J, Yang Y, Zhao Y, Bao H, Huang Y, Ma Y, Zhao H.
    BMC Cancer; 2024 Jul 03; 24(1):797. PubMed ID: 38961378
    [Abstract] [Full Text] [Related]

  • 52.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 53.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 54. Identifying optimal candidates for local treatment of the primary tumor among patients with de novo metastatic nasopharyngeal carcinoma: a retrospective cohort study based on Epstein-Barr virus DNA level and tumor response to palliative chemotherapy.
    Sun XS, Liu LT, Liu SL, Guo SS, Wen YF, Xie HJ, Tang QN, Liang YJ, Li XY, Yan JJ, Ma J, Chen QY, Tang LQ, Mai HQ.
    BMC Cancer; 2019 Jan 21; 19(1):92. PubMed ID: 30665378
    [Abstract] [Full Text] [Related]

  • 55.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 56.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 57. Induction chemotherapy followed by concurrent chemoradiotherapy versus concurrent chemoradiotherapy alone in stage III-IVb nasopharyngeal carcinoma patients with Epstein-Barr virus DNA ≥4000 copies/ml: a matched study.
    Guo SS, Tang LQ, Chen QY, Zhang L, Liu LT, Guo L, Mo HY, Luo DH, Huang PY, Xiang YQ, Sun R, Chen MY, Wang L, Lv X, Zhao C, Guo X, Cao KJ, Qian CN, Zeng MS, Bei JX, Hong MH, Shao JY, Sun Y, Ma J, Mai HQ.
    Oncotarget; 2016 May 17; 7(20):29739-48. PubMed ID: 27105538
    [Abstract] [Full Text] [Related]

  • 58.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 59.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 60.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 26.